GH Research
GH001 · 5-MeO-DMT, inhaled (mebufotenin) · Treatment-Resistant Depression
Company Overview
GH Research is a clinical-stage biopharmaceutical company developing GH001, a proprietary inhaled formulation of 5-MeO-DMT (mebufotenin), for treatment-resistant depression. Phase 2b was completed with results reported February 2025: -15.5-point MADRS reduction vs placebo (p<0.0001), with 57.5% remission vs 0% placebo at Day 8. Open-label extension data showed 73% remission at 6 months, with 77.8% of completers in remission. The FDA lifted a clinical hold on GH Research's IND on January 5, 2026, clearing the path for U.S. Phase 3 enrollment. GH002, an IV mebufotenin formulation, completed Phase 1 with IND submission expected. GH Research is one of the best-capitalized smaller psychedelic companies.
Pipeline
| Drug / Compound | Stage | Indication |
|---|---|---|
GH001 5-MeO-DMT, inhaled (mebufotenin) | Phase 2b Complete | Treatment-Resistant Depression |
GH001 5-MeO-DMT, inhaled (mebufotenin) | Phase 1 | Bipolar Depression |
GH002 5-MeO-DMT, IV (mebufotenin) | Phase 1 | Treatment-Resistant Depression |
Key Financials
- Cash Position
- $293.9M
- Burn Rate
- ~$15M/quarter
- Last Reported
- Q3 2025
Financial data is approximate. Always verify with official SEC filings.
Upcoming Catalysts
- 2026Phase 3 initiation for GH001 in TRD (U.S. enrollment cleared after FDA hold lift Jan 5, 2026)Clinical
Recent News
- 2026-01FDA lifts clinical hold on GH Research IND — U.S. Phase 3 enrollment now cleared for GH001
- 2025-02GH Research Phase 2b results: GH001 -15.5 MADRS vs placebo (p<0.0001), 57.5% remission at Day 8; OLE shows 73% remission at 6 months
News items are manually curated from public company press releases.
External Links
Looking for psychedelic therapy?
Browse our directory of 700+ verified ketamine and psychedelic therapy clinics across 49 states. Find providers near you who offer ketamine and psychedelic-assisted therapy.
Disclaimer: This page is for informational purposes only and does not constitute investment, medical, or financial advice. Pipeline status, financial figures, and catalyst dates are approximate and based on publicly available information as of 2026-02-25. Always consult official company filings and a qualified financial advisor before making investment decisions.